Leaflet CONBRIZA 20mg film-coated tablets
Product code: W54342003 Quantity: 84
Indicated for: osteoporosis
Route of administration: oral
Substance: bazedoxifene (selective estrogen receptor modulator)
ATC: G03XC02 (Genito urinary system and sex hormones | Other sex hormones and modulators of the genital system | Selective estrogen receptor modulators)
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Bazedoxifene is a selective estrogen receptor modulator (SERM) primarily used for the prevention and treatment of osteoporosis in postmenopausal women. It works by binding to estrogen receptors in bones, stimulating bone formation and reducing the risk of fractures, without stimulating breast or endometrial tissues.
Bazedoxifene is administered orally, usually once daily, and can be used alone or in combination with other hormonal therapies, such as conjugated estrogens. It is particularly indicated for women at high risk of osteoporosis who cannot use other treatments.
Common side effects include hot flashes, muscle cramps, nausea, and abdominal pain. In rare cases, severe adverse reactions such as deep vein thrombosis or strokes may occur. Regular evaluations are essential to monitor the efficacy and safety of the treatment.
Bazedoxifene is an effective therapeutic option for preventing bone loss and reducing fracture risk in postmenopausal women.
General data about CONBRIZA 20mg
- Substance: bazedoxifene
- Date of latest medicines list: 01-07-2013
- Product code: W54342003
- Concentration: 20mg
- Pharmaceutical form: film-coated tablets
- Quantity: 84
- Product type: Original
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.